Immunotherapy for Pancreatic Cancer: Peptidic Targeting of a Tumor-Specific Glycan [Video]

Register for this webinar: https://xtalks.com/webinars/immunotherapy-for-pancreatic-cancer-targeting-neu5gc-sialyl-lewisa-with-mgs5/?utm_source=youtube&utm_medium=sneakpreview&utm_campaign=24q038

Explore this webinar on a peptide ligand, called molecular guidance system 5 (MGS5), targeting N-glycolylneuraminic acid (Neu5Gc)-Sialyl LewisA in cancer, enhancing early detection and advancing liposome-based immunotherapy for pancreatic cancer. Glycosylation is a post-translation modification that is commonly altered in cancer, playing fundamental roles in cell signaling, cell migration and invasion, immune modulation and metastasis. Neu5Ac-Sialyl LewisA (CA19-9), part of the Lewis blood antigen family, is a well-studied blood biomarker that is Food and Drug Administration (FDA) approved for the detection of pancreatic cancer. However, its counterpart, N-glycolylneuraminic acid (Neu5Gc)-Sialyl LewisA, is under study in human malignancies due to the inactivation of the cytidine monophospho-N-acetylneuraminic acid hydroxylase (CMAH) gene and the absence of Neu5Gc-Sialyl LewisA specific targeting molecules.

This webinar will discuss a liposome-based immunotherapy (“Targeted Antigen Loaded Liposomes” TALL) that consists of three modular components: 1) pegylated stealth phospholipid layer, 2) an encapsulated synthetic immunogenic MHC class I restricted peptide derived from the measles virus and 3) MGS5 on the external surface for tumor targeting. MGS5 binds to the surface of the cancer cells via Neu5Gc-Sialyl LewisA and is subsequently internalized allowing for the internalization of the liposome and the release of the encapsulated antigenic peptide. This in turn elicits a robust immune response. TALL, in combination with an anti-programmed cell death protein 1 (PD-1) inhibitor, results in a 10-fold reduction in tumor burden in mice bearing orthotopic breast and pancreatic tumors, compared to using anti-PD-1 alone.

Join this webinar to learn not only how MGS5 is a novel peptide for the detection of Neu5Gc- Sialyl LewisA, but it can also serve as a therapeutically relevant cancer targeting agent allowing for the delivery of therapeutics.

#Immunotherapy #Cancer #DrugDelivery #ImmunoOncology #ClinicalResearch #PancreaticCancer #CRO #Oncology #Biomarkers #CancerImmunotherapy #CellGeneTherapies